MEDBOT-B (02252): Chang Zhaohua, Shiratani Taisuke, Ashida Naruhiro, and Liang Min were appointed as non-executive directors.

MEDBOT-B (02252) Announcement: Dr. Chang Zhaohua, Mr. Bai Tengtai, Mr. Lutian Nianyu, and Ms. Liang Min have been appointed as non-executive directors, effective from the end of the temporary shareholders meeting; Dr. Liu Guoen and Mr. Zhou Jiahong have been appointed as independent non-executive directors, effective from the end of the temporary shareholders meeting; Dr. Chang Zhaohua has been further appointed as the Chairman of the Board, effective from November 25, 2025. The Board of Directors hereby announces the change in the composition of the Board Committees from November 25, 2025 as follows: the Audit Committee consists of independent non-executive director Mr. Zhou Jiahong, Mr. Zhong Weiwen, and non-executive director Mr. Lutian Nianyu, with Mr. Zhou Jiahong as the Chairman; the Remuneration and Appraisal Committee consists of independent non-executive director Dr. Liu Guoen, Mr. Zhou Jiahong, and non-executive director Mr. Lutian Nianyu, with Dr. Liu Guoen as the Chairman; the Nomination Committee consists of independent non-executive director Mr. Yao Haisong, Mr. Zhong Weiwen, and non-executive director Ms. Liang Min, with Mr. Yao Haisong as the Chairman; the Strategic Development Committee consists of independent non-executive director Dr. Liu Guoen, non-executive director Mr. Bai Tengtai, and executive director Dr. He Chao, with Dr. Liu Guoen as the Chairman; and the Commercialization Committee consists of non-executive director Mr. Bai Tengtai, Mr. Chen Chen, executive director Mr. Liu Yu, and non-executive director Ms. Liang Min, with Mr. Bai Tengtai as the Chairman. The Board of Directors hereby announces that Mr. Sun Hongbin will no longer serve as the authorized representative of the Company as stipulated in Rule 3.05 of the listing rules, and Dr. Chang Zhaohua will replace Mr. Sun Hongbin as the authorized representative of the Company, effective from November 25, 2025.